Glenmark Pharmaceuticals
BSE: 532296 | NSE: GLENMARK | ISIN: INE935A01035 | SECTOR: Biotechnology & DrugsOpen
1,029.65High
1,038.70Low
1,020.60Prev Close
1,042.70P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
290.61BVolume
17.78KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
1,029.85Ask
1,030.90
Company Description
- Biotechnology & Drugs
BSE
532296NSE
GLENMARKISIN
INE935A01035
Glenmark Pharmaceuticals Limited is an India-based global pharmaceutical company. The Company is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The Company has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.
Company Officers
Glenn Saldanha
Executive Chairman of the Board, Managing DirectorV. S. Mani
Global Chief Financial Officer, Executive DirectorHarish Kuber
Compliance Officer, Company SecretaryCherylann Pinto
Executive Director - Corporate Services